文献类型：期刊文献

英文题名：Clinicopathological Significance and Prognostic Values of Long Noncoding RNA BCYRN1 in Cancer Patients: A Meta-Analysis and Bioinformatics Analysis

作者：Han, Xiaoyong[1,2,3];Wang, Yongfeng[4];Zhao, Rangyin[4];Zhang, Guangming[4];Qin, Chenhui[1];Fu, Liangyin[4];Jin, Haojie[5];Jiang, Xianglai[1];Yang, Kehu[6];Cai, Hui[2,3,7]

第一作者：Han, Xiaoyong

通信作者：Cai, H[1];Cai, H[2];Cai, H[3]

机构：[1]Ning Xia Med Univ, Grad Sch, Yinchuan 750004, Ningxia, Peoples R China;[2]Gansu Prov Hosp, Gen Surg Clin Med Ctr, Lanzhou 730000, Gansu, Peoples R China;[3]Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gans, Lanzhou 730000, Gansu, Peoples R China;[4]Gansu Univ Chinese Med, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China;[5]Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China;[6]Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou 730000, Peoples R China;[7]Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumor, Lanzhou 730000, Peoples R China

第一机构：Ning Xia Med Univ, Grad Sch, Yinchuan 750004, Ningxia, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Gen Surg Clin Med Ctr, Lanzhou 730000, Gansu, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gans, Lanzhou 730000, Gansu, Peoples R China;[3]corresponding author), Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumor, Lanzhou 730000, Peoples R China.

年份：2022

卷号：2022

外文期刊名：JOURNAL OF ONCOLOGY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000872024000001)】；

基金：This study was supported by grants from the Central to Guide Local Scientific and Technological Development (ZYYDDFFZZJ-1), Key Talent Project of Gansu Province of the Organization Department of Gansu Provincial Party Committee (2020RCXM076), Key Laboratory of Gastrointestinal Cancer Diagnosis and Treatment of National Health Commission (2019PT320005), Gansu Provincial Youth Science and Technology Fund Program (21JR7RA642), Gansu Key Laboratory of Molecular Diagnosis and Precision Treatment of Surgical Tumors (18JR2RA033), Guiding Plan for Scientific and Technological Development of Lanzhou (2019-ZD-102), and Natural Science Foundation of Gansu Province (21JR11RA186).

语种：英文

摘要：Background. Although combination therapies have substantially improved the clinical outcomes of cancer patients, the prognosis and early diagnosis remain unsatisfactory. As a result, it is critical to look for novel indicators linked to cancer. Despite a number of recent studies indicating that the lncRNA brain cytoplasmic RNA1(BCYRN1) may be a potential predictive biomarker in cancer patients, BCYRN1's prognostic value is still being debated. Methods. We utilized PubMed, Embase, Web of Science, and the Cochrane Library to search for studies related to BCYRN1 until October 2021. Valid data were extracted after determining the articles according to the inclusion and exclusion criteria, and forest plots were made using Stata software. We used hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals to evaluate the relationship between abnormal BCYRN1 expression and patient prognosis and clinicopathological characteristics. Results. Meta-analysis revealed that increased BCYRN1 expression was associated with both overall tumor survival (OS; HR =1.84, 95% CI 1.51-2.25, p < 0.0001) and disease-free survival (DFS; HR = 1.65, 95% CI 1.20-2.26, p = 0.002). Furthermore, a strong association was discovered between increased BCYRN1 expression and tumor invasion depth (OR = 2.11, 95% CI 1.49-2.99, p = 0.000), clinical stage (OR = 2.52, 95% CI 1.18-5.37, p = 0.017), and distant tumor metastasis (OR = 4.19, 95% CI 1.45-12.05, p = 0.008). Conclusions. We found that high BCYRN1 expression was associated with poor survival prognosis and aggressive clinicopathological characteristics in various cancers, indicating that it is a potential prognostic indicator as well as a therapeutic target. Further research is needed on pan-cancer cohorts to determine the clinical relevance of BCYRN1 in distinct cancer types.